# A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer

> **NCT03258398** · PHASE2 · COMPLETED · sponsor: **Effector Therapeutics** · enrollment: 56 (actual)

## Conditions studied

- Microsatellite Stable Relapsed or Refractory Colorectal Cancer

## Interventions

- **DRUG:** eFT508
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03258398
- **Lead sponsor:** Effector Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-18
- **Primary completion:** 2019-03-26
- **Final completion:** 2019-05-13
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2019-07-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03258398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03258398, "A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03258398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*